BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004;101:4649-54. [PMID: 15070772 DOI: 10.1073/pnas.0400590101] [Cited by in Crossref: 217] [Cited by in F6Publishing: 193] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Macedo AC, Balouch S, Tabet N. Is Sleep Disruption a Risk Factor for Alzheimer’s Disease? JAD 2017;58:993-1002. [DOI: 10.3233/jad-161287] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
2 Petrovich GD. Learning and the motivation to eat: forebrain circuitry. Physiol Behav 2011;104:582-9. [PMID: 21549730 DOI: 10.1016/j.physbeh.2011.04.059] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
3 Kodama T, Usui S, Honda Y, Kimura M. High Fos expression during the active phase in orexin neurons of a diurnal rodent, Tamias sibiricus barberi. Peptides 2005;26:631-8. [DOI: 10.1016/j.peptides.2004.11.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
4 Moore MW, Akladious A, Hu Y, Azzam S, Feng P, Strohl KP. Effects of orexin 2 receptor activation on apnea in the C57BL/6J mouse. Respir Physiol Neurobiol 2014;200:118-25. [PMID: 24929062 DOI: 10.1016/j.resp.2014.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
5 De la Herrán-Arita AK, García-García F. Current and emerging options for the drug treatment of narcolepsy. Drugs 2013;73:1771-81. [PMID: 24122734 DOI: 10.1007/s40265-013-0127-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
6 Nishino S, Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, Kanbayashi T. Hypocretin/orexin and narcolepsy: new basic and clinical insights. Acta Physiol (Oxf) 2010;198:209-22. [PMID: 19555382 DOI: 10.1111/j.1748-1716.2009.02012.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
7 Guilleminault C, Cao MT. Narcolepsy. Principles and Practice of Sleep Medicine. Elsevier; 2011. pp. 957-68. [DOI: 10.1016/b978-1-4160-6645-3.00085-2] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
8 Sakai N, Chikahisa S, Nishino S. Stimulants in Excessive Daytime Sleepiness. Sleep Medicine Clinics 2010;5:591-607. [DOI: 10.1016/j.jsmc.2010.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
10 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
11 Wu MF, Nienhuis R, Maidment N, Lam HA, Siegel JM. Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy. J Neurosci 2011;31:6305-10. [PMID: 21525270 DOI: 10.1523/JNEUROSCI.0365-11.2011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
12 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Willie JT, Renthal W, Chemelli RM, Miller MS, Scammell TE, Yanagisawa M, Sinton CM. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005;130:983-95. [PMID: 15652995 DOI: 10.1016/j.neuroscience.2004.10.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 3.8] [Reference Citation Analysis]
14 Ma S, Hangya B, Leonard CS, Wisden W, Gundlach AL. Dual-transmitter systems regulating arousal, attention, learning and memory. Neurosci Biobehav Rev 2018;85:21-33. [PMID: 28757457 DOI: 10.1016/j.neubiorev.2017.07.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
15 Dauvilliers Y, Arnulf I. Narcolepsie avec cataplexie. Revue Neurologique 2008;164:634-45. [DOI: 10.1016/j.neurol.2007.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Perez-Leighton CE, Butterick-Peterson TA, Billington CJ, Kotz CM. Role of orexin receptors in obesity: from cellular to behavioral evidence. Int J Obes (Lond) 2013;37:167-74. [PMID: 22391883 DOI: 10.1038/ijo.2012.30] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
17 Monoi N, Matsuno A, Nagamori Y, Kimura E, Nakamura Y, Oka K, Sano T, Midorikawa T, Sugafuji T, Murakoshi M, Uchiyama A, Sugiyama K, Nishino H, Urade Y. Japanese sake yeast supplementation improves the quality of sleep: a double-blind randomised controlled clinical trial. J Sleep Res 2016;25:116-23. [PMID: 26354605 DOI: 10.1111/jsr.12336] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
18 Papolos D, Mattis S, Golshan S, Molay F. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes. J Affect Disord 2009;118:28-38. [PMID: 19631388 DOI: 10.1016/j.jad.2009.06.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
19 Tisdale RK, Yamanaka A, Kilduff TS. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future. Sleep 2021;44:zsaa278. [PMID: 33313880 DOI: 10.1093/sleep/zsaa278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep 2015;7:51-61. [PMID: 26045680 DOI: 10.2147/NSS.S56077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
21 Revel FG, Gottowik J, Gatti S, Wettstein JG, Moreau J. Rodent models of insomnia: A review of experimental procedures that induce sleep disturbances. Neuroscience & Biobehavioral Reviews 2009;33:874-99. [DOI: 10.1016/j.neubiorev.2009.03.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
22 Winsky-Sommerer R, Boutrel B, de Lecea L. Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry. Mol Neurobiol 2005;32:285-94. [PMID: 16385142 DOI: 10.1385/MN:32:3:285] [Cited by in Crossref: 91] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
23 Sokołowska P, Urbańska A, Biegańska K, Wagner W, Ciszewski W, Namiecińska M, Zawilska JB. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci 2014;52:48-55. [PMID: 24243084 DOI: 10.1007/s12031-013-0165-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
24 Takenoshita S, Nishino S. Pharmacologic Management of Excessive Daytime Sleepiness. Sleep Med Clin 2020;15:177-94. [PMID: 32386693 DOI: 10.1016/j.jsmc.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Tanaka S, Toyoda H, Honda Y, Seki Y, Sakurai T, Honda K, Kodama T. Hypocretin/orexin prevents recovery from sickness. Biomed Rep 2015;3:648-50. [PMID: 26405539 DOI: 10.3892/br.2015.491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Saitoh A, Tominaga H, Ogawa Y, Irukayama-Tomobe Y, Yamada M, Yanagisawa M, Nagase H. Effects of the delta opioid receptor agonist KNT-127 on electroencephalographic activity in mice. Pharmacol Rep 2018;70:350-4. [PMID: 29477045 DOI: 10.1016/j.pharep.2017.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Pintwala S, Peever J. Circuit mechanisms of sleepiness and cataplexy in narcolepsy. Current Opinion in Neurobiology 2017;44:50-8. [DOI: 10.1016/j.conb.2017.02.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
28 Arias-Carrión O, Murillo-Rodriguez E, Xu M, Blanco-Centurion C, Drucker-Colín R, Shiromani PJ. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27:1465-70. [PMID: 15683135 DOI: 10.1093/sleep/27.8.1465] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
29 Matsuki T, Sakurai T. Orexins and Orexin Receptors: From Molecules to Integrative Physiology. In: Civelli O, Zhou Q, editors. Orphan G Protein-Coupled Receptors and Novel Neuropeptides. Berlin: Springer Berlin Heidelberg; 2008. pp. 27-55. [DOI: 10.1007/400_2007_047] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Reference Citation Analysis]
30 Hong C, Byrne NJ, Zamlynny B, Tummala S, Xiao L, Shipman JM, Partridge AT, Minnick C, Breslin MJ, Rudd MT, Stachel SJ, Rada VL, Kern JC, Armacost KA, Hollingsworth SA, O'Brien JA, Hall DL, McDonald TP, Strickland C, Brooun A, Soisson SM, Hollenstein K. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. Nat Commun 2021;12:815. [PMID: 33547286 DOI: 10.1038/s41467-021-21087-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
31 Arias-Carrión O, Drucker-Colín R, Murillo-Rodríguez E. Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett 2006;404:93-7. [PMID: 16762505 DOI: 10.1016/j.neulet.2006.05.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
32 Nishino S, Okuro M. Emerging treatments for narcolepsy and its related disorders. Expert Opin Emerg Drugs 2010;15:139-58. [PMID: 20166851 DOI: 10.1517/14728210903559852] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
33 Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32:451-62. [PMID: 21565412 DOI: 10.1016/j.tips.2011.03.007] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 12.6] [Reference Citation Analysis]
34 Székely M. Orexins, energy balance, temperature, sleep-wake cycle. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2006;291:R530-2. [DOI: 10.1152/ajpregu.00179.2006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
35 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
36 Recabarren M, Valdés J, Farías P, Serón-ferré M, Torrealba F. Differential effects of infralimbic cortical lesions on temperature and locomotor activity responses to feeding in rats. Neuroscience 2005;134:1413-22. [DOI: 10.1016/j.neuroscience.2005.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
37 Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26. [PMID: 21525292 DOI: 10.1523/JNEUROSCI.6506-10.2011] [Cited by in Crossref: 134] [Cited by in F6Publishing: 78] [Article Influence: 12.2] [Reference Citation Analysis]
38 Burgess CR, Scammell TE. Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci 2012;32:12305-11. [PMID: 22956821 DOI: 10.1523/JNEUROSCI.2630-12.2012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
39 Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects. Journal of Clinical Psychopharmacology 2013;33:363-70. [DOI: 10.1097/jcp.0b013e31828f5a7a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Logan Black J. Narcolepsy: A review of evidence for autoimmune diathesis. International Review of Psychiatry 2009;17:461-9. [DOI: 10.1080/02646830500381492] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
41 Prober DA, Rihel J, Onah AA, Sung RJ, Schier AF. Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci 2006;26:13400-10. [PMID: 17182791 DOI: 10.1523/JNEUROSCI.4332-06.2006] [Cited by in Crossref: 308] [Cited by in F6Publishing: 153] [Article Influence: 20.5] [Reference Citation Analysis]
42 Jiang H, Huang J, Shen Y, Guo S, Wang L, Han C, Liu L, Ma K, Xia Y, Li J, Xu X, Xiong N, Wang T. RBD and Neurodegenerative Diseases. Mol Neurobiol 2017;54:2997-3006. [PMID: 27032389 DOI: 10.1007/s12035-016-9831-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
43 Haq IZ, Naidu Y, Reddy P, Chaudhuri KR. Narcolepsy in Parkinson's disease. Expert Rev Neurother 2010;10:879-84. [PMID: 20518604 DOI: 10.1586/ern.10.56] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
44 Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019;12:1756286419875622. [PMID: 31632459 DOI: 10.1177/1756286419875622] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
45 Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009;61:162-76. [PMID: 19549926 DOI: 10.1124/pr.109.001321] [Cited by in Crossref: 314] [Cited by in F6Publishing: 284] [Article Influence: 26.2] [Reference Citation Analysis]
46 Kaushik MK, Aritake K, Imanishi A, Kanbayashi T, Ichikawa T, Shimizu T, Urade Y, Yanagisawa M. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. Proc Natl Acad Sci U S A 2018;115:6046-51. [PMID: 29784823 DOI: 10.1073/pnas.1722686115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
47 Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, Gouda H, Kumagai H, Fujii H, Yanagisawa M, Nagase H. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem 2015;58:7931-7. [PMID: 26267383 DOI: 10.1021/acs.jmedchem.5b00988] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
48 Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. Advances in pharmaceutical treatment options for narcolepsy. Expert Opinion on Orphan Drugs 2018;6:597-610. [DOI: 10.1080/21678707.2018.1521267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Brisbare-roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007;13:150-5. [DOI: 10.1038/nm1544] [Cited by in Crossref: 396] [Cited by in F6Publishing: 371] [Article Influence: 26.4] [Reference Citation Analysis]
50 Mieda M, Sakurai T. Overview of orexin/hypocretin system. Orexin/Hypocretin System. Elsevier; 2012. pp. 5-14. [DOI: 10.1016/b978-0-444-59489-1.00002-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
51 De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R. Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2011;2:26. [PMID: 21541306 DOI: 10.3389/fneur.2011.00026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
52 Urbańska A, Sokołowska P, Woldan-Tambor A, Biegańska K, Brix B, Jöhren O, Namiecińska M, Zawilska JB. Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures. J Mol Neurosci 2012;46:10-7. [PMID: 21547533 DOI: 10.1007/s12031-011-9526-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
53 Liu M, Thankachan S, Kaur S, Begum S, Blanco-Centurion C, Sakurai T, Yanagisawa M, Neve R, Shiromani PJ. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008;28:1382-93. [PMID: 18973565 DOI: 10.1111/j.1460-9568.2008.06446.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
54 Matsuki T, Nomiyama M, Takahira H, Hirashima N, Kunita S, Takahashi S, Yagami K, Kilduff TS, Bettler B, Yanagisawa M, Sakurai T. Selective loss of GABA(B) receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. Proc Natl Acad Sci U S A 2009;106:4459-64. [PMID: 19246384 DOI: 10.1073/pnas.0811126106] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 6.2] [Reference Citation Analysis]
55 Messina A, Monda M, Valenzano A, Messina G, Villano I, Moscatelli F, Cibelli G, Marsala G, Polito R, Ruberto M, Carotenuto M, Monda V, Viggiano A, Daniele A, Nigro E. Functional Changes Induced by Orexin A and Adiponectin on the Sympathetic/Parasympathetic Balance. Front Physiol 2018;9:259. [PMID: 29623046 DOI: 10.3389/fphys.2018.00259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
56 Willie JT, Lim MM, Bennett RE, Azarion AA, Schwetye KE, Brody DL. Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice. J Neurotrauma 2012;29:1908-21. [PMID: 22607167 DOI: 10.1089/neu.2012.2404] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
57 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
58 Sinton CM. Animal Models of Narcolepsy: Development, Findings and Perspectives. In: Goswami M, Pandi-perumal SR, Thorpy MJ, editors. Narcolepsy. New York: Springer; 2010. pp. 23-37. [DOI: 10.1007/978-1-4419-0854-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Cao M, Guilleminault C. Hypocretin and its emerging role as a target for treatment of sleep disorders. Curr Neurol Neurosci Rep 2011;11:227-34. [PMID: 21170610 DOI: 10.1007/s11910-010-0172-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
60 Kodadek T, Cai D. Chemistry and biology of orexin signaling. Mol Biosyst 2010;6:1366-75. [PMID: 20532299 DOI: 10.1039/c003468a] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
61 Sakurai T, Yanagisawa M, Mieda M. Rodent Models of Human Narcolepsy-cataplexy. In: de Lecea L, Sutcliffe JG, editors. Hypocretins. Boston: Springer US; 2005. pp. 27-38. [DOI: 10.1007/0-387-25446-3_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Karnani MM, Schöne C, Bracey EF, González JA, Viskaitis P, Li HT, Adamantidis A, Burdakov D. Role of spontaneous and sensory orexin network dynamics in rapid locomotion initiation. Prog Neurobiol 2020;187:101771. [PMID: 32058043 DOI: 10.1016/j.pneurobio.2020.101771] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
63 Nishino S, Mignot E. Wake-Promoting Medications: Basic Mechanisms and Pharmacology. Principles and Practice of Sleep Medicine. Elsevier; 2005. pp. 468-83. [DOI: 10.1016/b0-72-160797-7/50045-8] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
64 Papuć E, Stelmasiak Z, Grieb P, Paweł G, Rejdak K. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci Lett 2010;474:9-12. [PMID: 20193740 DOI: 10.1016/j.neulet.2010.02.062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
65 Ikeno T, Yan L. A comparison of the orexin receptor distribution in the brain between diurnal Nile grass rats (Arvicanthis niloticus) and nocturnal mice (Mus musculus). Brain Res 2018;1690:89-95. [PMID: 29630859 DOI: 10.1016/j.brainres.2018.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
66 Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci 2019;20:83-93. [PMID: 30546103 DOI: 10.1038/s41583-018-0097-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 18.7] [Reference Citation Analysis]
67 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Liguori C, Nuccetelli M, Izzi F, Sancesario G, Romigi A, Martorana A, Amoroso C, Bernardini S, Marciani MG, Mercuri NB, Placidi F. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiology of Aging 2016;40:120-6. [DOI: 10.1016/j.neurobiolaging.2016.01.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
69 Mohammed M, Yanagisawa M, Blessing W, Ootsuka Y. Attenuated cold defense responses in orexin neuron-ablated rats. Temperature (Austin) 2016;3:465-75. [PMID: 28349086 DOI: 10.1080/23328940.2016.1184366] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
70 Akintomide GS, Rickards H. Narcolepsy: a review. Neuropsychiatr Dis Treat 2011;7:507-18. [PMID: 21931493 DOI: 10.2147/NDT.S23624] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
71 Fujimoto T, Rikimaru K, Fukuda K, Sugimoto H, Masuda K, Ohyabu N, Banno Y, Tokunaga N, Kawamoto T, Tomata Y, Kumagai Y, Iida M, Nagano Y, Yoneyama-hirozane M, Shimizu Y, Sasa K, Ishikawa T, Yukitake H, Ito M, Aoyama K, Matsumoto T. Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.1c00626] [Reference Citation Analysis]
72 Zhang W, Fukuda Y, Kuwaki T. Respiratory and cardiovascular actions of orexin-A in mice. Neuroscience Letters 2005;385:131-6. [DOI: 10.1016/j.neulet.2005.05.032] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
73 Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, Cauley JA, Redline S, Hillier TA, Cummings SR, Yaffe K; SOF Research Group. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol 2011;70:722-32. [PMID: 22162057 DOI: 10.1002/ana.22468] [Cited by in Crossref: 267] [Cited by in F6Publishing: 240] [Article Influence: 26.7] [Reference Citation Analysis]
74 Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T. Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol (1985) 2007;103:1772-9. [PMID: 17717124 DOI: 10.1152/japplphysiol.00075.2007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 5.4] [Reference Citation Analysis]
75 Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 2013;7:28. [PMID: 23616752 DOI: 10.3389/fnbeh.2013.00028] [Cited by in Crossref: 135] [Cited by in F6Publishing: 136] [Article Influence: 15.0] [Reference Citation Analysis]
76 Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511. [PMID: 17292770 DOI: 10.1016/S0140-6736(07)60237-2] [Cited by in Crossref: 471] [Cited by in F6Publishing: 147] [Article Influence: 31.4] [Reference Citation Analysis]
77 Maruyama T, Matsumura M, Sakai N, Nishino S. The pathogenesis of narcolepsy, current treatments and prospective therapeutic targets. Expert Opinion on Orphan Drugs 2015;4:63-82. [DOI: 10.1517/21678707.2016.1117973] [Reference Citation Analysis]
78 Yukitake H, Fujimoto T, Ishikawa T, Suzuki A, Shimizu Y, Rikimaru K, Ito M, Suzuki M, Kimura H. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacology Biochemistry and Behavior 2019;187:172794. [DOI: 10.1016/j.pbb.2019.172794] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
79 Dresler M, Spoormaker V, Beitinger P, Czisch M, Kimura M, Steiger A, Holsboer F. Neuroscience-driven discovery and development of sleep therapeutics. Pharmacology & Therapeutics 2014;141:300-34. [DOI: 10.1016/j.pharmthera.2013.10.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
80 Hong ZY, Huang ZL, Qu WM, Eguchi N. Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol Sin 2005;26:155-9. [PMID: 15663891 DOI: 10.1111/j.1745-7254.2005.00523.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
81 Nishino S, Mignot E. Narcolepsy and cataplexy. Sleep Disorders. Elsevier; 2011. pp. 783-814. [DOI: 10.1016/b978-0-444-52007-4.00007-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
82 Nishino S, Mignot E. Wake-Promoting Medications. Principles and Practice of Sleep Medicine. Elsevier; 2011. pp. 510-26. [DOI: 10.1016/b978-1-4160-6645-3.00044-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Zhang B, Guo D, Han L, Rensing N, Satoh A, Wong M. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2020;134:104615. [PMID: 31605778 DOI: 10.1016/j.nbd.2019.104615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
84 De la Herrán-arita AK, Equihua-benítez AC, Drucker-colín R. Treatment of cataplexy. Expert Opinion on Orphan Drugs 2013;1:199-210. [DOI: 10.1517/21678707.2013.765359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
85 Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014;262:8-13. [PMID: 24406723 DOI: 10.1016/j.bbr.2013.12.045] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
86 Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009;10:829-35. [PMID: 19616998 DOI: 10.1016/j.sleep.2009.05.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
87 Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 2005;9:231-41. [PMID: 15961331 DOI: 10.1016/j.smrv.2004.07.007] [Cited by in Crossref: 196] [Cited by in F6Publishing: 172] [Article Influence: 11.5] [Reference Citation Analysis]
88 Deutschman CS, Raj NR, McGuire EO, Kelz MB. Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis. Crit Care Med 2013;41:e368-75. [PMID: 24105451 DOI: 10.1097/CCM.0b013e31828e9843] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
89 Wei W, Motoike T, Krzeszinski JY, Jin Z, Xie XJ, Dechow PC, Yanagisawa M, Wan Y. Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action. Cell Metab 2014;19:927-40. [PMID: 24794976 DOI: 10.1016/j.cmet.2014.03.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
90 Sakurai T. Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regulatory Peptides 2005;126:3-10. [DOI: 10.1016/j.regpep.2004.08.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
91 Nishino S, Kotorii N. Overview of Management of Narcolepsy. In: Goswami M, Pandi-perumal SR, Thorpy MJ, editors. Narcolepsy. New York: Springer; 2010. pp. 251-65. [DOI: 10.1007/978-1-4419-0854-4_23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
92 Iio K, Saitoh T, Ohshita R, Hino T, Amezawa M, Takayama Y, Nagumo Y, Yamamoto N, Kutsumura N, Irukayama-tomobe Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Discovery of Orexin 2 Receptor Selective and Dual Orexin Receptor Agonists based on the Tetralin Structure: Switching of Receptor Selectivity by Chirality on the Tetralin Ring. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.128555] [Reference Citation Analysis]
93 de Lecea L. Optogenetic control of hypocretin (orexin) neurons and arousal circuits. Curr Top Behav Neurosci 2015;25:367-78. [PMID: 25502546 DOI: 10.1007/7854_2014_364] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
94 Takenoshita S, Nishino S. Pharmacologic Management of Excessive Daytime Sleepiness. Sleep Med Clin 2017;12:461-78. [PMID: 28778242 DOI: 10.1016/j.jsmc.2017.03.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
95 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
96 Snow MB, Fraigne JJ, Thibault-Messier G, Chuen VL, Thomasian A, Horner RL, Peever J. GABA Cells in the Central Nucleus of the Amygdala Promote Cataplexy. J Neurosci 2017;37:4007-22. [PMID: 28209737 DOI: 10.1523/JNEUROSCI.4070-15.2017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
97 Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Göder R, Aldenhoff JB, Hinze-Selch D. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 2011;12:941-6. [PMID: 22036605 DOI: 10.1016/j.sleep.2011.06.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
98 De La Herrán-Arita AK, Zomosa-Signoret VC, Millán-Aldaco DA, Palomero-Rivero M, Guerra-Crespo M, Drucker-Colín R, Vidaltamayo R. Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice. Neuroscience 2011;183:134-43. [PMID: 21435382 DOI: 10.1016/j.neuroscience.2011.03.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
99 Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci 2012;1264:72-86. [PMID: 22803681 DOI: 10.1111/j.1749-6632.2012.06585.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
100 Sanchez-Espinosa MP, Atienza M, Cantero JL. Sleep deficits in mild cognitive impairment are related to increased levels of plasma amyloid-β and cortical thinning. Neuroimage 2014;98:395-404. [PMID: 24845621 DOI: 10.1016/j.neuroimage.2014.05.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
101 Chowdhury S, Hung CJ, Izawa S, Inutsuka A, Kawamura M, Kawashima T, Bito H, Imayoshi I, Abe M, Sakimura K, Yamanaka A. Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice. Elife 2019;8:e44927. [PMID: 31159922 DOI: 10.7554/eLife.44927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
102 Agee LA, Nemchek V, Malone CA, Lee HJ, Monfils MH. Appetitive Behavior in the Social Transmission of Food Preference Paradigm Predicts Activation of Orexin-A producing Neurons in a Sex-Dependent Manner. Neuroscience 2022;481:30-46. [PMID: 34843892 DOI: 10.1016/j.neuroscience.2021.11.032] [Reference Citation Analysis]
103 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
104 Sundvik M, Panula P. Interactions of the orexin/hypocretin neurones and the histaminergic system. Acta Physiol (Oxf) 2015;213:321-33. [PMID: 25484194 DOI: 10.1111/apha.12432] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
105 De la Herrán-arita AK, Drucker-colín R. Models for narcolepsy with cataplexy drug discovery. Expert Opinion on Drug Discovery 2012;7:155-64. [DOI: 10.1517/17460441.2012.651454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Wurtman RJ. Narcolepsy and the hypocretins. Metabolism 2006;55:S36-9. [DOI: 10.1016/j.metabol.2006.07.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
107 Mignot E. Narcolepsy. Principles and Practice of Sleep Medicine. Elsevier; 2011. pp. 938-56. [DOI: 10.1016/b978-1-4160-6645-3.00084-0] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
108 Fujiki N, Cheng T, Yoshino F, Nishino S. Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Exp Neurol 2009;217:46-54. [PMID: 19416673 DOI: 10.1016/j.expneurol.2009.01.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
109 Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep–wake disorders. The Lancet Neurology 2005;4:673-82. [DOI: 10.1016/s1474-4422(05)70196-4] [Cited by in Crossref: 102] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
110 Ritchie C, Okuro M, Kanbayashi T, Nishino S. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. Curr Neurol Neurosci Rep 2010;10:180-9. [PMID: 20425033 DOI: 10.1007/s11910-010-0100-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
111 Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014;13:600-13. [PMID: 24849861 DOI: 10.1016/S1474-4422(14)70075-4] [Cited by in Crossref: 173] [Cited by in F6Publishing: 60] [Article Influence: 21.6] [Reference Citation Analysis]
112 Petrovich GD, Hobin MP, Reppucci CJ. Selective Fos induction in hypothalamic orexin/hypocretin, but not melanin-concentrating hormone neurons, by a learned food-cue that stimulates feeding in sated rats. Neuroscience 2012;224:70-80. [PMID: 22922124 DOI: 10.1016/j.neuroscience.2012.08.036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
113 Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z. Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target. Curr Pharm Des 2019;25:4208-20. [PMID: 31663471 DOI: 10.2174/1381612825666191029101830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
114 Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008;131:2734-41. [PMID: 18718966 DOI: 10.1093/brain/awn193] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
115 Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87. [PMID: 17910982 DOI: 10.1016/j.yfrne.2007.08.001] [Cited by in Crossref: 178] [Cited by in F6Publishing: 162] [Article Influence: 11.9] [Reference Citation Analysis]
116 De Lecea L, Sutcliffe JG. The hypocretins and sleep: The hypocretins and sleep. FEBS Journal 2005;272:5675-88. [DOI: 10.1111/j.1742-4658.2005.04981.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
117 Sakurai T. Orexin deficiency and narcolepsy. Curr Opin Neurobiol 2013;23:760-6. [PMID: 23663890 DOI: 10.1016/j.conb.2013.04.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
118 Willie JT, Takahira H, Shibahara M, Hara J, Nomiyama M, Yanagisawa M, Sakurai T. Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice. J Mol Neurosci 2011;43:155-61. [PMID: 20711757 DOI: 10.1007/s12031-010-9437-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
119 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
120 Dell’osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC. Wake-Promoting Pharmacotherapy for Psychiatric Disorders. Curr Psychiatry Rep 2014;16. [DOI: 10.1007/s11920-014-0524-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
121 Teske JA, Mavanji V. Energy expenditure: role of orexin. Vitam Horm 2012;89:91-109. [PMID: 22640610 DOI: 10.1016/B978-0-12-394623-2.00006-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
122 Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012;91:975-85. [PMID: 22549286 DOI: 10.1038/clpt.2011.370] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
123 Parmar A, Murray BJ, Narang I. Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy. Curr Neurol Neurosci Rep 2020;20:38. [PMID: 32651734 DOI: 10.1007/s11910-020-01057-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
124 Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EA, Kukkonen JP. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26. European Journal of Pharmacology 2018;837:137-44. [DOI: 10.1016/j.ejphar.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
125 Boutrel B, de Lecea L. Addiction and arousal: the hypocretin connection. Physiol Behav. 2008;93:947-951. [PMID: 18262574 DOI: 10.1016/j.physbeh.2007.11.022] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
126 Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012;9:739-52. [PMID: 23065655 DOI: 10.1007/s13311-012-0150-9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 81] [Article Influence: 13.4] [Reference Citation Analysis]
127 McGregor R, Wu MF, Barber G, Ramanathan L, Siegel JM. Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level. J Neurosci 2011;31:15455-67. [PMID: 22031892 DOI: 10.1523/JNEUROSCI.4017-11.2011] [Cited by in Crossref: 64] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
128 Wang Z, Liu S, Kakizaki M, Hirose Y, Ishikawa Y, Funato H, Yanagisawa M, Yu Y, Liu Q. Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway. J Biol Chem 2014;289:31950-9. [PMID: 25278019 DOI: 10.1074/jbc.M114.600015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
129 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
130 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
131 Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Medicine Reviews 2005;9:253-68. [DOI: 10.1016/j.smrv.2005.01.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
132 Machaalani R, Hunt NJ, Waters KA. Effects of changes in energy homeostasis and exposure of noxious insults on the expression of orexin (hypocretin) and its receptors in the brain. Brain Res 2013;1526:102-22. [PMID: 23830852 DOI: 10.1016/j.brainres.2013.06.035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
133 Chen L, Brown RE, McKenna JT, McCarley RW. Animal models of narcolepsy. CNS Neurol Disord Drug Targets 2009;8:296-308. [PMID: 19689311 DOI: 10.2174/187152709788921717] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
134 Nishino S, Fujiki N. Neuropeptides as possible targets in sleep disorders. Expert Opin Ther Targets 2007;11:37-59. [PMID: 17150033 DOI: 10.1517/14728222.11.1.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
135 Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system--where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56. [PMID: 16990828 DOI: 10.1038/ncpneuro0300] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
136 Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-47. [PMID: 18160631 DOI: 10.1523/JNEUROSCI.3878-07.2007] [Cited by in Crossref: 186] [Cited by in F6Publishing: 78] [Article Influence: 13.3] [Reference Citation Analysis]
137 Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R. Understanding sleep-wake mechanisms and drug discovery. Expert Opin Drug Discov 2017;12:643-57. [PMID: 28511597 DOI: 10.1080/17460441.2017.1329818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
138 Blanco-Centurion C, Bendell E, Zou B, Sun Y, Shiromani PJ, Liu M. VGAT and VGLUT2 expression in MCH and orexin neurons in double transgenic reporter mice. IBRO Rep 2018;4:44-9. [PMID: 30155524 DOI: 10.1016/j.ibror.2018.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
139 Cao M. Advances in narcolepsy. Med Clin North Am 2010;94:541-55. [PMID: 20451031 DOI: 10.1016/j.mcna.2010.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
140 Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opinion on Pharmacotherapy 2017;18:809-17. [DOI: 10.1080/14656566.2017.1323877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
141 Barateau L, Lopez R, Dauvilliers Y. Treatment Options for Narcolepsy. CNS Drugs 2016;30:369-79. [PMID: 27155860 DOI: 10.1007/s40263-016-0337-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
142 Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep 2017;9:39-57. [PMID: 28424564 DOI: 10.2147/NSS.S103467] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 9.4] [Reference Citation Analysis]
143 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Li SB, Borniger JC, Yamaguchi H, Hédou J, Gaudilliere B, de Lecea L. Hypothalamic circuitry underlying stress-induced insomnia and peripheral immunosuppression. Sci Adv 2020;6:eabc2590. [PMID: 32917689 DOI: 10.1126/sciadv.abc2590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
145 Koesema E, Kodadek T. Global analysis of gene expression mediated by OX1 orexin receptor signaling in a hypothalamic cell line. PLoS One 2017;12:e0188082. [PMID: 29145494 DOI: 10.1371/journal.pone.0188082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Sakurai T, Mieda M, Tsujino N. The orexin system: roles in sleep/wake regulation: Orexin and sleep/wake state. Annals of the New York Academy of Sciences 2010;1200:149-61. [DOI: 10.1111/j.1749-6632.2010.05513.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 10.4] [Reference Citation Analysis]
147 Samson WK, Bagley SL, Ferguson AV, White MM. Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2007;292:R382-7. [DOI: 10.1152/ajpregu.00496.2006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
148 de Biase S, Nilo A, Gigli GL, Valente M. Investigational therapies for the treatment of narcolepsy. Expert Opin Investig Drugs 2017;26:953-63. [PMID: 28726523 DOI: 10.1080/13543784.2017.1356819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
149 Yakupov EZ, Artemieva DV, Troshina YV. [Multimodality of clinical effects of orexin]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:114-9. [PMID: 30698570 DOI: 10.17116/jnevro2018118121114] [Reference Citation Analysis]
150 Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8:171-81. [DOI: 10.1038/nrn2092] [Cited by in Crossref: 763] [Cited by in F6Publishing: 716] [Article Influence: 50.9] [Reference Citation Analysis]
151 Mignot E. Narcolepsy. Principles and Practice of Sleep Medicine. Elsevier; 2017. pp. 855-872.e7. [DOI: 10.1016/b978-0-323-24288-2.00089-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
152 Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol 2016;18. [DOI: 10.1007/s11940-016-0429-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
153 Mäkelä KA, Wigren HK, Zant JC, Sakurai T, Alhonen L, Kostin A, Porkka-Heiskanen T, Herzig KH. Characterization of sleep-wake patterns in a novel transgenic mouse line overexpressing human prepro-orexin/hypocretin. Acta Physiol (Oxf) 2010;198:237-49. [PMID: 20003098 DOI: 10.1111/j.1748-1716.2009.02068.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
154 Cui S, Huang Y, Cui X, Zhao H, Hu X, Liu Y, Qin Y, Kurban N, Zhang Y. A common neuronal mechanism of hypertension and sleep disturbances in spontaneously hypertensive rats: Role of orexinergic neurons. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020;100:109902. [DOI: 10.1016/j.pnpbp.2020.109902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Van de Bittner GC, Van de Bittner KC, Wey HY, Rowe W, Dharanipragada R, Ying X, Hurst W, Giovanni A, Alving K, Gupta A, Hoekman J, Hooker JM. Positron Emission Tomography Assessment of the Intranasal Delivery Route for Orexin A. ACS Chem Neurosci 2018;9:358-68. [PMID: 29035509 DOI: 10.1021/acschemneuro.7b00357] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
156 Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opinion on Investigational Drugs 2007;16:1785-97. [DOI: 10.1517/13543784.16.11.1785] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
157 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
158 Hewagalamulage SD, Clarke IJ, Young IR, Rao A, Henry BA. High cortisol response to adrenocorticotrophic hormone identifies ewes with reduced melanocortin signalling and increased propensity to obesity. J Neuroendocrinol 2015;27:44-56. [PMID: 25315658 DOI: 10.1111/jne.12233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
159 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
160 Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83-90. [PMID: 23359095 DOI: 10.1007/s40263-012-0036-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
161 Barateau L, Liblau R, Peyron C, Dauvilliers Y. Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. CNS Drugs 2017;31:821-34. [DOI: 10.1007/s40263-017-0464-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
162 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
163 Samson WK, Bagley SL, Ferguson AV, White MM. Orexin receptor subtype activation and locomotor behaviour in the rat. Acta Physiol (Oxf) 2010;198:313-24. [PMID: 19889100 DOI: 10.1111/j.1748-1716.2009.02056.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
164 Ellis J, Pediani JD, Canals M, Milasta S, Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 2006;281:38812-24. [PMID: 17015451 DOI: 10.1074/jbc.M602494200] [Cited by in Crossref: 163] [Cited by in F6Publishing: 68] [Article Influence: 10.2] [Reference Citation Analysis]
165 Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013;36:325-36. [PMID: 23449602 DOI: 10.5665/sleep.2442] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
166 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
167 Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev 2012;92:1087-187. [PMID: 22811426 DOI: 10.1152/physrev.00032.2011] [Cited by in Crossref: 700] [Cited by in F6Publishing: 590] [Article Influence: 70.0] [Reference Citation Analysis]
168 Upton N. In Vivo Pharmacology of Orexin (Hypocretin) Receptors. In: de Lecea L, Sutcliffe JG, editors. Hypocretins. Boston: Springer US; 2005. pp. 205-20. [DOI: 10.1007/0-387-25446-3_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
169 Lee J, Reddy MM, Kodadek T. Discovery Of An Orexin Receptor Positive Potentiator. Chem Sci 2010;1. [PMID: 24409338 DOI: 10.1039/C0SC00197J] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
170 Sellayah D, Sikder D. Food for Thought: Understanding the Multifaceted Nature of Orexins. Endocrinology 2013;154:3990-9. [DOI: 10.1210/en.2013-1488] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
171 Elliott JE, De Luche SE, Churchill MJ, Moore C, Cohen AS, Meshul CK, Lim MM. Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice. Sleep 2018;41. [PMID: 29315422 DOI: 10.1093/sleep/zsx212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
172 Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35:1625-35. [PMID: 23204605 DOI: 10.5665/sleep.2232] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
173 Rogers AA, Aiani LM, Blanpain LT, Yuxian S, Moore R, Willie JT. Deep brain stimulation of hypothalamus for narcolepsy-cataplexy in mice. Brain Stimul 2020;13:1305-16. [PMID: 32320748 DOI: 10.1016/j.brs.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Seong MJ, Hong SB. Autoimmunity and Immunotherapy in Narcolepsy. Sleep Med Res 2017;8:1-7. [DOI: 10.17241/smr.2017.00052] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
175 Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol 2009;89:193-219. [PMID: 19654034 DOI: 10.1016/j.pneurobio.2009.07.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
176 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
177 Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 2007;8:427-40. [PMID: 17475553 DOI: 10.1016/j.sleep.2007.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
178 Szabadi E. Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug Discovery Today 2014;19:701-8. [DOI: 10.1016/j.drudis.2014.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
179 Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A 2017;114:5731-6. [PMID: 28507129 DOI: 10.1073/pnas.1700499114] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
180 Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, Yanagisawa M. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 2009;9:64-76. [PMID: 19117547 DOI: 10.1016/j.cmet.2008.10.010] [Cited by in Crossref: 176] [Cited by in F6Publishing: 173] [Article Influence: 13.5] [Reference Citation Analysis]
181 Stone EA, Lin Y, Ahsan MR, Quartermain D. Evidence of roles of central alpha1-adrenoceptors and epinephrine in orexin A-induced hyperactivity in mice. Neurosci Lett 2005;381:325-8. [PMID: 15896493 DOI: 10.1016/j.neulet.2005.02.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
182 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
183 Hu B, Yang N, Qiao QC, Hu ZA, Zhang J. Roles of the orexin system in central motor control. Neurosci Biobehav Rev 2015;49:43-54. [PMID: 25511388 DOI: 10.1016/j.neubiorev.2014.12.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
184 Thannickal TC. A decade of hypocretin/orexin: Accomplishments in sleep medicine. Sleep Medicine Reviews 2009;13:5-8. [DOI: 10.1016/j.smrv.2008.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Blanco-Centurion C, Liu M, Konadhode R, Pelluru D, Shiromani PJ. Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. Sleep 2013;36:31-40. [PMID: 23288969 DOI: 10.5665/sleep.2296] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
186 Petrovich GD. Forebrain networks and the control of feeding by environmental learned cues. Physiol Behav 2013;121:10-8. [PMID: 23562305 DOI: 10.1016/j.physbeh.2013.03.024] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 7.8] [Reference Citation Analysis]
187 Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009;98:2501-15. [PMID: 19025760 DOI: 10.1002/jps.21604] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
188 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
189 Elbaz I, Yelin-Bekerman L, Nicenboim J, Vatine G, Appelbaum L. Genetic ablation of hypocretin neurons alters behavioral state transitions in zebrafish. J Neurosci 2012;32:12961-72. [PMID: 22973020 DOI: 10.1523/JNEUROSCI.1284-12.2012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
190 Kantor S, Mochizuki T, Lops SN, Ko B, Clain E, Clark E, Yamamoto M, Scammell TE. Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. Sleep 2013;36:1129-38. [PMID: 23904672 DOI: 10.5665/sleep.2870] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
191 Liu M, Blanco-Centurion C, Konadhode R, Begum S, Pelluru D, Gerashchenko D, Sakurai T, Yanagisawa M, van den Pol AN, Shiromani PJ. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci 2011;31:6028-40. [PMID: 21508228 DOI: 10.1523/JNEUROSCI.6069-10.2011] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
192 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
193 Jones BE. Arousal and sleep circuits. Neuropsychopharmacology 2020;45:6-20. [PMID: 31216564 DOI: 10.1038/s41386-019-0444-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
194 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
195 Hondo M, Furutani N, Yamasaki M, Watanabe M, Sakurai T. Orexin neurons receive glycinergic innervations. PLoS One 2011;6:e25076. [PMID: 21949857 DOI: 10.1371/journal.pone.0025076] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
196 Zhou S, Yamashita A, Su J, Zhang Y, Wang W, Hao L, Yamanaka A, Kuwaki T. Activity of putative orexin neurons during cataplexy. Mol Brain 2022;15:21. [PMID: 35246205 DOI: 10.1186/s13041-022-00907-w] [Reference Citation Analysis]
197 Spinieli RL, Ben Musa R, Cornelius-green J, Hasser EM, Cummings KJ. Orexin facilitates the ventilatory and behavioral responses of rats to hypoxia. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. [DOI: 10.1152/ajpregu.00334.2021] [Reference Citation Analysis]
198 Kostin A, Siegel JM, Alam MN. Lack of hypocretin attenuates behavioral changes produced by glutamatergic activation of the perifornical-lateral hypothalamic area. Sleep 2014;37:1011-20. [PMID: 24790280 DOI: 10.5665/sleep.3680] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
199 Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience 2012;218:138-53. [DOI: 10.1016/j.neuroscience.2012.05.033] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
200 Hirai N, Nishino S. Recent Advances in the Treatment of Narcolepsy. Curr Treat Options Neurol 2011;13:437-57. [DOI: 10.1007/s11940-011-0137-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
201 Arias-Carrión O, Murillo-Rodríguez E. Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. PLoS One 2014;9:e95342. [PMID: 24736646 DOI: 10.1371/journal.pone.0095342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
202 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
203 Toossi H, Del Cid-Pellitero E, Jones BE. GABA Receptors on Orexin and Melanin-Concentrating Hormone Neurons Are Differentially Homeostatically Regulated Following Sleep Deprivation. eNeuro 2016;3:ENEURO. [PMID: 27294196 DOI: 10.1523/ENEURO.0077-16.2016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]